12:00 AM
 | 
Nov 15, 2010
 |  BC Week In Review  |  Company News  |  Other News

Advanced Life, Abbott, Pfizer infectious news

Advanced Life said it submitted a proposal to NIH's National Institute of Allergy and Infectious Diseases (NIAID) to develop an IV formulation of Restanza cethromycin. The proposal requests $38 million over...

Read the full 144 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >